Catalent Pharma Solutions announced earlier this week it is investing up to $40 million at its manufacturing facility in Winchester.

According to media reports, the investment will include new equipment to increase the site’s tablet and capsule manufacturing capabilities and capacity.

“Our Winchester facility provides customers with a high degree of flexible manufacturing solutions and has a proven track record of success with technology transfers and product launches,” Catalent Winchester general manager Rick Tucker said in a company press release. “We have a clear investment strategy at the site that is not only driven by immediate customer needs, but also looks to the future in anticipation of demand and new technologies.”

Validations for the new equipment are expected to be completed in the coming months, according to Catalent. In 2015, the site also underwent a $35 million facility investment that doubled its footprint to 180,000 square-feet.

The current investment is the latest in a series of recent investments by Catalent. In April, the company announced a $14 million expansion to expand integrated turnkey softgel capabilities at its facility in Eberbach, Germany, and a $5 million investment to expand its OptiMelt hot melt extrusion capabilities at its Somerset, New Jersey, drug development center.